Webinar: Results of the DISCO-MS Trial with Dr. John Corboy

 
   

The DISCO-MS trial looked at the question “Can we define a population of patients in whom it’s safe to discontinue their disease modifying therapy (DMT) for MS as they age?” Dr. John Corboy presents the findings in this webinar. 

Your opinions help us shape future education events! Take our brief survey at https://www.surveymonkey.com/r/RSGMGPZ

About the Presenter

Dr. John Corboy is the Medical Director of the Rocky Mountain MS Center and Director of the RMMSC at University of Colorado. He is a graduate of University of Pennsylvania and did his neurology residency there, with a fellowship at Johns Hopkins University in Baltimore. He specialized in MS and neurovirology at the University of Minnesota Medical Center before coming to Colorado in 1994. In 1997, he founded the University of Colorado Multiple Sclerosis Center, now transformed into the Rocky Mountain Multiple Sclerosis Center at University of Colorado, a multidisciplinary group offering state-of-the-art care and research to multiple sclerosis patients. Dr. Corboy is the founding editor of Neurology: Clinical Practice, the clinical journal of the American Academy of Neurology.

Thanks to our Supporters

This Empower MS Educational Series is presented in part by Rocky Mountain MS Center supporters, including patient education grants and/or sponsorships from Bristol Myers Squibb, Genentech and Sanofi Genzyme.

If you were not able to tune in, please CLICK HERE to view the webinar.

 

The Rocky Mountain MS Center's Webinar Series is made possible in part by grants from:

Biogen.svg    EMD Serono     Genentech Roche   sanofi genzyme